Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study
Marco Ruella(Parker Institute for Cancer Immunotherapy), Liliana Devizzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Guido Gini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Anna Russo(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Corradini(Gruppo di Ricerca Geriatrica), Corrado Tarella(A. O. Ordine Mauriziano di Torino), Umberto Ricardi(University of Turin), Massimo Di Nicola(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Ladetto(University of Turin), Michele Magni(A. O. Ordine Mauriziano di Torino), Riccardo Bruna(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paola Matteucci(University of Milan), Daniele Caracciolo(Magna Graecia University), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Andrea Riccardo Filippi(University of Turin), Guido Parvis(A. O. Ordine Mauriziano di Torino), Attilio Olivieri(Ospedali Riuniti di Ancona)
International Journal of Radiation Oncology*Biology*Physics
December 17, 2015
Cited by 48
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646